Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ: ARGX )

659.81 -5.38 (-0.81%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 450,778
Open 667.19
Bid (Size) 551.00 (1)
Ask (Size) 661.06 (1)
Prev. Close 665.19
Today's Range 658.26 - 667.82
52wk Range 349.86 - 678.21
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
argenx Highlights 2025 Strategic Priorities
From argenx SE
Via GlobeNewswire

Performance

YTD
+6.39%
+6.39%
1 Month
+3.37%
+3.37%
3 Month
+21.32%
+21.32%
6 Month
+41.42%
+41.42%
1 Year
+77.16%
+77.16%

More News

Read More
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
argenx to Present at 43rd Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Looking Into argenx's Recent Short Interest
Via Benzinga
argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy
From argenx SE
Via GlobeNewswire
Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval
Via Benzinga
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
From argenx SE
Via GlobeNewswire
(ARGX) - Analyzing argenx's Short Interest
Via Benzinga
Peering Into argenx's Recent Short Interest
Via Benzinga
The Latest Analyst Ratings For argenx
Via Benzinga
This Bristol-Myers Squibb Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
From Zai Lab Limited
Via Business Wire
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
From argenx SE
Via GlobeNewswire
This eBay Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
argenx to Participate at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Argenx Q3 Revenue, EPS Beats Excite Bullish Biotech Analysts: 'Most Enviable I&I Pipeline In Entire Industry'
Via Benzinga
This Atlassian Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Via Benzinga
This Huntington Ingalls Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
From argenx SE
Via GlobeNewswire
argenx Highlights Data Showing Patient Impact Across Multiple Immunology Programs at 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions
From argenx SE
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.